Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (IMLFF)

Inmed Pharmaceuticals Inc (IMLFF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

, /PRNewswire/ -  ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER, BC , Nov. 25, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Announces Election of Directors

, /PRNewswire/ - ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Announces Election of Directors

VANCOUVER, BC , Nov. 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

, /PRNewswire/ - ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

, /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

VANCOUVER, BC , Nov. 16, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

, /PRNewswire/ -  ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
IIROC Trade Resumption - IN

IIROC Trade Resumption - IN

IMLFF : 4.8800 (-1.61%)
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

, /PRNewswire/ -  ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical...

IMLFF : 4.8800 (-1.61%)
INM : 3.45 (-4.70%)
IN.TO : 4.50 (-5.26%)
IIROC Trading Halt - IN

IIROC Trading Halt - IN

IMLFF : 4.8800 (-1.61%)
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

VANCOUVER, BC , Nov. 12, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 4.8800 (-1.61%)
IN.TO : 4.50 (-5.26%)
INM : 3.45 (-4.70%)
InMed Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 6, 2020 / InMed Pharmaceuticals, Inc. (OTCQX:IMLFF) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on November 6, 2020...

IMLFF : 4.8800 (-1.61%)
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

, /PRNewswire/ -  ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical...

IN.TO : 4.50 (-5.26%)
IMLFF : 4.8800 (-1.61%)
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020

VANCOUVER, BC , Nov. 5, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 4.8800 (-1.61%)
IN.TO : 4.50 (-5.26%)
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 4.50 (-5.26%)
IMLFF : 4.8800 (-1.61%)
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020

TSX:IN OTCQX:IMLFF

IN.TO : 4.50 (-5.26%)
IMLFF : 4.8800 (-1.61%)
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 4.50 (-5.26%)
IMLFF : 4.8800 (-1.61%)
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

, /PRNewswire/ -  ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IN.TO : 4.50 (-5.26%)
IMLFF : 4.8800 (-1.61%)
InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing

TSX:IN OTCQX:IMLFF

IN.TO : 4.50 (-5.26%)
IMLFF : 4.8800 (-1.61%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar